Why the study?
What is the tissue distribution and plasma concentration of adriamycin after IV and hepatic IA administration in patients with solid tumors?
What is the tissue distribution and plasma concentration of adriamycin after IV and hepatic IA administration in patients with solid tumors?
Adriamycin concentrates highest in the liver and tumor tissue, with hepatic intraarterial administration yielding higher metabolite concentrations than intravenous administration.
Case-level data on adriamycin distribution are hypothesis-generating; leaves open whether IA delivery improves outcomes versus IV.
Twenty patients with solid tumors received 30 mg/M2 of adriamycin. Various tissue samples were intraoperatively obtained from 18 patients, about 1.5--5 hours after an intravenous (IV) bolus dose. Normal liver showed the highest levels of adriamycin uptake (2.3--19.8 micrograms/g); lymph nodes were second; muscle and bone marrow, next; fat and skin had the lowest adriamycin uptake (0.04--0.40 microgram/g). Tumor tissue, excluding that with much necrosis and hemorrhaging, had adriamycin concentrations which approximated those of the liver (1.1--9.2 micrograms/g). Six patients, all with hepatic malignancies, had prolonged plasma concentration studies after IV administration; 5 also had adriamycin administered directly into the hepatic artery catheter. Adriamycin-plasma-time courses were similar, whether the drug was administered by bolus directly into the hepatic artery or peripheral vein. The concentration of metabolites after hepatic intraarterial administration was definitely higher than that after IV administration. Patients with hepatic dysfunction had delayed plasma clearance and secondarily elevated levels approximately 160 and 300 minutes after administration.
No takes yet. Share an insight, caveat, or question.
Lee et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: